Ehsan Khedre | Biology and Life Sciences | Best Researcher Award

Dr. Ehsan Khedre | Biology and Life Sciences | Best Researcher Award

Egyptian Drug Authority Pyramids Branch | Egypt

Dr. Ehsan Khedre is a pharmaceutical biochemistry researcher whose work spans natural product pharmacology, nanotechnology, oxidative stress, and metabolic disease. After earning her B.Pharm (Ain-Shams University, Egypt, 2004), she completed an M.Sc. in Biochemistry (Zagazig University, 2011) and a Ph.D. (Al-Azhar University, 2018) on estrogenic effects of quercetin and its nanoparticles. She has held roles at Egypt’s National Organization for Drug Control & Research (NODCAR / EDA), advancing from drug control specialist to quality manager and researcher in biochemical laboratories. Her publication record (to date > 9 peer-reviewed articles) includes studies on hepatic fibrosis, nanocarrier enhancement of phytochemicals, metabolic syndrome models, and nanoparticle biodistribution. Her citation metrics h-index of 5, total documents 7, total citations 170 reflect her growing impact in pharmacology and toxicology. Her research interests include antioxidant and anti-inflammatory natural compounds, nanoparticle delivery systems, biochemical mechanisms of organ injury, and translational approaches to metabolic and hepatic diseases. She has also contributed by serving as reviewer for journals, receiving training in quality systems (ISO 9001 / ISO 17025), scientific writing, bioinformatics, and innovation, and participating in workshops on research skills. In sum, Dr. Khedre combines deep domain expertise, laboratory leadership, and interdisciplinary scholarship to advance discovery and application of therapeutics.

Profiles : Orcid | Scopus

Featured Publications

Fayed, E. A., El-Sebaey, S. A., Ebrahim, M. A., Abu-Elfotuh, K., El-Sayed Mansour, R., Mohamed, E. K., Hamdan, A. M. E., Al-subaie, F. T., Albalawi, G. S., Albalawi, T. M., et al. (2025). Discovery of novel bicyclic and tricyclic cyclohepta[b]thiophene derivatives as multipotent AChE and BChE inhibitors, in-vivo and in-vitro assays, ADMET and molecular docking simulation. European Journal of Medicinal Chemistry, 117201.

Abu-Elfotuh, K., Kamel, G. A. M., Najm, M. A. A., Hamdan, A. M. E., Koullah, M. T., Fahmy, R. K. E., Aboelsoud, H. A., Alghusn, M. A., Albalawi, B. R., Atwa, A. M., et al. (2025). Modulating multiple molecular trajectories by nutraceuticals and/or physical activity in attention-deficit/hyperactivity disorder (ADHD)-like behaviors in rat pups. Journal of NeuroImmune Pharmacology.

Oudah, K. H., Najm, M. A. A., Ramsis, T. M., Ebrahim, M. A., Gohar, N. A., Abu-Elfotuh, K., Mohamed, E. K., Hamdan, A. M. E., Hamdan, A. M., Almotairi, R., et al. (2025). Unlocking therapeutic potential of novel thieno-oxazepine hybrids as multi-target inhibitors of AChE/BChE and evaluation against Alzheimer’s disease: In vivo, in vitro, histopathological, and docking studies. Pharmaceuticals, 18(8), 1214.

Nazeam, J. A., Black, I., Mulamoottil, V. A., Selim, N. M., El Shiekh, R. A., Abu-Elfotuh, K., Hamdan, A. M. E., Gowifel, A. M. H., Hafez, S. M., Mohamed, E. K., et al. (2025). Okra seed polysaccharides mitigate neuroinflammation and cognitive impairment via modulation of Nrf2/HO-1, HMGB1/RAGE/TLR4/NF-κB, NLRP3/Caspase-1, JAK-2/STAT-3, AMPK/SIRT1/m-TOR, PI3K/AKT/CREB/BDNF/TrkB and PERK/CHOP/Bcl-2 axes. International Immunopharmacology, 114110.

Mohamed, E. K., Fathy, M. M., Sadek, N. A., & Eldosoki, D. E. (2024). The effects of rutin coat on the biodistribution and toxicities of iron oxide nanoparticles in rats. Journal of Nanoparticle Research, 26(3), 49.

Avinash Kumar | Biology and Life Sciences | Best Researcher Award

Assist. Prof. Dr. Avinash Kumar | Biology and Life Sciences | Best Researcher Award

Long Island University Arnold and Marie Schwartz College of Pharmacy and Health Sciences | United States

Assist. Prof. Dr. Avinash Kumar, Ph.D., is an Assistant Professor at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY. With a Ph.D. in Biotechnology from the University of Pune, India, his doctoral work focused on biochemical and biophysical characterization of class II α-mannosidases. He completed postdoctoral research at the University of Mississippi Medical Center and National Center for Cell Science, India, investigating transcriptional and post-translational programs driving prostate cancer progression. His research aims to develop personalized and precision medicine strategies targeting metastatic and high-risk prostate cancer, including health disparities in African American men. Dr. Kumar utilizes high-throughput single-cell genomics, transcriptomics, and proteomics in combination with genetically engineered and xenograft mouse models, patient tissues, and complementary cell line studies. He has mentored numerous graduate, undergraduate, and Pharm.D. students, directed the Molecular Imaging Core at LIU, and actively serves on institutional committees and as a reviewer for top journals. Dr. Kumar has published 28 peer-reviewed articles, 5 book chapters, and over 20 conference abstracts, with an h-index of 17 , 873 citations, and 29 publications. He has received multiple fellowships, awards, and research grants and continues to advance translational cancer therapeutics through rigorous preclinical and mechanistic studies.

Profile : Scopus | Orcid

Featured Publications

“Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer”

“The Therapeutic Efficacy and Mechanism of Action of Gnetin C, a Natural Compound from the Melinjo Plant,     Preclinical Mouse Model of Advanced Prostate Cancer”

“AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for       development of cancer therapeutics”

“Data from Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer”

“Supplementary Figure 1-2; Supplementary Table 1-4 from Dietary Pterostilbene for MTA1-Targeted Interception   in   High- Risk Premalignant Prostate Cancer”